Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from SynAct Pharma AB ( (SE:SYNACT) ) is now available.
SynAct Pharma will host a Capital Markets Day in Stockholm on March 11, 2026, to brief investors, analysts, and media on its clinical development programs and strategic priorities. The event comes ahead of key clinical data from the ADVANCE study and ongoing trials in respiratory viral infections and dengue, underscoring management’s view that 2026 could be a pivotal year for the company’s pipeline and positioning in inflammation resolution therapies.
The most recent analyst rating on (SE:SYNACT) stock is a Hold with a SEK22.00 price target. To see the full list of analyst forecasts on SynAct Pharma AB stock, see the SE:SYNACT Stock Forecast page.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm that focuses on resolving inflammation by selectively activating the melanocortin system. Its portfolio includes oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and inflammation-resolving activity, targeting conditions such as rheumatoid arthritis and respiratory viral infections.
YTD Price Performance: -3.98%
Average Trading Volume: 123,614
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.16B
See more data about SYNACT stock on TipRanks’ Stock Analysis page.